<DOC>
	<DOCNO>NCT00245362</DOCNO>
	<brief_summary>To evaluate safety effectiveness CG8020 CG2505 .</brief_summary>
	<brief_title>A Phase II Trial CG 8020 CG 2505 Patients With Nonresectable Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>To evaluate clinical laboratory safety CG 8020 CG 2505 evaluate efficacy CG 8020 CG 2505 measure clinical benefit response , progression-free survival , survival CA 19-9 serum marker level chemotherapy naive experienced patient nonresectable metastatic adenocarcinoma pancreas</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologic cytologic diagnosis nonresectable metastatic pancreatic adenocarcinoma Chemotherapy na√Øve chemotherapy experience pancreatic cancer Prior cancer vaccine gene therapy History clinically significant autoimmune disease ( eg , systemic lupus erythematosus , sarcoidosis , rheumatoid arthritis , glomerulonephritis , vasculitis ) History another malignancy past five year , except adequately treat nonmelanomatous skin cancer superficial bladder cancer carcinomainsitu cervix , unless approve Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>cancer vaccine</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>unresectable pancreatic cancer</keyword>
	<keyword>immunotherapy</keyword>
</DOC>